🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,762 results for “CTI” Clear

  1. POMALIDOMIDE, POMALIDOMIDE, POMALIDOMIDE, POMALIDOMIDE, DARZALEX 1800 mg solution for injection, DEXAMETHASONE, DEXAMETHASONE

    Wuhan Createrna Science and Technology Co., Ltd

    Relapsed/refractory multiple myeloma

    phase 2 small molecule active

    1 trial

  2. PROLEUKIN® 18 x 106 IU Powder for solution for injection or infusion, Lifileucel, Cyclophosphamide Injection 1 g, FLUDARABINE

    Iovance Biotherapeutics B.V.

    Previously treated advanced melanoma

    phase 2 small molecule active

    1 trial

  3. Paclitaxel Kabi 6 mg/ml koncentrátum oldatos infúzióhoz, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATINE MEDAC 10 mg/mL, solution à diluer pour perfusion, 68Ga-FAPI-46, DOXORUBICINE ARROW 2 mg/ml, solution pour perfusion, Epirubicin Eugia 2 mg/ml oplossing voor injectie, Cyclophosphamid beta 500 mg/ml Konzentrat zur Herstellung einer Injektions-/Infusionslösung

    The George Institute

    Breast cancer

    phase 2 small molecule active

    1 trial

  4. Paclitaxel Polymeric Micelles for Injection and Cisplatin combined with Cadonilimab

    The First People's Hospital of Lianyungang

    Locally Advanced Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  5. Parenteral Remodulin (treprostinil) injection

    United Therapeutics Europe Ltd

    Pulmonary Arterial Hypertension

    phase 2 small molecule terminated

    1 trial

  6. Pectin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Slow Transit Constipation

    phase 2 small molecule active

    1 trial

  7. Pegasys 180 micrograms solution for injection in pre-filled syringe, VIR-3434, Viread 245 mg film-coated tablets, VIR-2218

    Vir Biotechnology

    Chronic Hepatitis B Virus (HBV) Infection

    phase 2 small molecule active

    1 trial

  8. Pemazyre 4.5 mg tablets

    Ningbo Cancer Hospital

    Recurrent or metastatic solid cancer harboring a FGFR1,2 ,3 fusion/rearrangement or activating mutation, outside of the approved indications for any selective FGFR inhibitor in France

    phase 2 small molecule active

    1 trial

  9. Pembrolizumab Injection

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  10. Pentasa Sachet 2 g depotgranulat, Pentasa PLACEBO Sachet 2g in the granule formulation specifically designed to resemble the active drug product

    The George Institute

    Lynch syndrome, which is increasing the risk of developing colorectal cancer

    phase 2 small molecule active

    1 trial

  11. Phage Therapy

    Adaptive Biotechnologies Corp

    Prosthetic Joint Infection

    phase 2 mab terminated

    2 trials

  12. Phase 1b/2, Multicenter, Open-label, Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3-DXd monotherapy and combinations in Patients with inoperable advanced breast cancer (ABC) after progression on T-DXd- (ICARUS BREAST 2)

    The George Institute

    Patients with HER2-positive (HER2-pos) (cohort 1) or HER2-low defined as a score 1+ on immunohistochemistry [IHC] or as an IHC score 2+ and negative results on in situ hybridization (ISH) (cohort 2) ABC, and any hormone receptor (HR) status, who have progressed on trastuzumab deruxtecan (T-DXd). In addition to previous T-DXd, patients with HER2-pos tumors must have received prior treatment with trastuzumab (+/- pertuzumab) and taxanes and may have received T-DM1. Patients with HER2-low tumors must have received prior treatment with taxanes. Patients with HR-positive (HR+) and HER2-low tumor must have received prior treatment with endocrine therapy and CDK4/6 inhibitors.

    phase 2 other active

    1 trial

  13. Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants with Heart Failure with Preserved Ejection Fraction and Left Ventricular Hypertrophy.

    NovoThirteen

    Heart Failure with Preserved Ejection Fraction and Left Ventricular Hypertrophy.

    phase 2 other active

    1 trial

  14. Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants with Heart Failure with Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy.

    NovoThirteen

    Heart Failure with Reduced/Mildly Reducede Ejection Fraction and Left Ventricular Hypertrophy.

    phase 2 other active

    1 trial

  15. Placebo

    Theravance Biopharma Ireland Umited

    Chronic Obstructive Pulmonary Disease, COPD

    phase 2 small molecule completed

    1 trial

  16. Placebo

    IRONWOOD PHARMACEUTICALS INC

    Functional Constipation in Children Ages 6-17 Years

    phase 2 small molecule completed

    1 trial

  17. Placebo

    Takeda

    Graft Rejection

    phase 2 mab completed

    1 trial

  18. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Addiction

    phase 2 small molecule completed

    1 trial

  19. Placebo + Inactive Marijuana (0% THC)

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Use

    phase 2 small molecule completed

    1 trial

  20. Placebo - Sodium Chloride 9 mg/ml (0.9%) - Solution for injection, ARO-DM1

    Sarepta Therapeutics

    Type 1 Myotonic Dystrophy

    phase 2 small molecule active

    1 trial

  21. Placebo A, NNC0519-0130, Ozempic 0.5 mg solution for injection in pre-filled pen

    NovoThirteen

    Chronic Kidney Disease, with or without Type 2 diabetes, Obesity

    phase 2 small molecule active

    1 trial

  22. Placebo A, Semaglutide B Placebo, Ozempic 0.5 mg solution for injection in pre-filled pen

    NovoThirteen

    type 2 diabetes

    phase 2 small molecule active

    1 trial

  23. Placebo PH20 SC – prefilled syringe (placebo to Efgartigimod PH20 SC – prefilled syringe), Efgartigimod

    argenx

    Antibody-Mediated Rejection

    phase 2 small molecule active

    1 trial

  24. Placebo comparator, intramuscular injection, TRI-001

    Ferring Pharmaceuticals

    Patients with Chronic Limb Threatening Ischemia (CLTI) due to Peripheral Arterial Disease (PAD)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources